The benefits of frexalimab in people with relapsing MS have been sustained for up to three years in a clinical trial, data ...

The company announced positive Phase 1 results for a subcutaneous formulation of Briumvi, evaluating it against the currently ...

A new PET imaging approach that measures synaptic density in the spinal cord provides a quantitative way to assess the ...

Higher-dose ocrelizumab produced greater peripheral B-cell depletion than the approved 600 mg regimen in two phase 3b trials ...

Immunic Inc (NASDAQ:IMUX, FRA:10VA) said on Thursday it presented three posters at the 2026 Consortium of Multiple Sclerosis ...

The MSAA is expanding its patient-centered research network to include more than 1,000 people with MS receiving care at 20 ...

THIRUVANANTHAPURAM: Merin Theres John, a native of Pathanamthitta, was just 20 and sitting for her BCom examination when the ...

Shares of TG Therapeutics rose after the company reported positive data for new subcutaneous formulation of a multiple sclerosis treatment. The stock climbed 12%, to $41.21, Wednesday afternoon and is ...

MS diagnosis means adapting to a new reality – but it can also bring a fresh perspective, says Katie O’Loughlin (44) ...